Intervacc AB enters into a commercial production phase with Strangvac®.
Intervacc has signed a Letter of Intent and an agreement on first mile stones with 3P Biopharmaceuticals in Pamplona, Spain, for contract manufacturing of Strangvac®, Intervacc´s recombinant vaccine against strangles. The collaboration between the Companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.“We are very pleased about this agreement, this is a significant step forward for Intervacc, which thereby enters into a new commercial production phase after successful completion of clinical trials and safety